Regeneron Pharmaceuticals, Inc.
REGN
$558.87
$13.412.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.95B | 3.61B | 3.61B | 3.44B | 3.03B |
| Total Other Revenue | 81.90M | 179.40M | 114.20M | 104.50M | 116.90M |
| Total Revenue | 3.03B | 3.79B | 3.72B | 3.55B | 3.15B |
| Cost of Revenue | 1.79B | 1.98B | 1.76B | 1.68B | 1.68B |
| Gross Profit | 1.24B | 1.81B | 1.96B | 1.87B | 1.46B |
| SG&A Expenses | 633.00M | 792.20M | 714.40M | 758.80M | 689.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 14.60M | -- |
| Total Operating Expenses | 2.42B | 2.77B | 2.48B | 2.45B | 2.37B |
| Operating Income | 604.00M | 1.02B | 1.24B | 1.09B | 773.80M |
| Income Before Tax | 905.00M | 958.10M | 1.49B | 1.63B | 700.70M |
| Income Tax Expenses | 96.30M | 40.40M | 152.40M | 195.80M | -21.30M |
| Earnings from Continuing Operations | 808.70M | 917.70M | 1.34B | 1.43B | 722.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 808.70M | 917.70M | 1.34B | 1.43B | 722.00M |
| EBIT | 604.00M | 1.02B | 1.24B | 1.09B | 773.80M |
| EBITDA | 730.90M | 1.15B | 1.37B | 1.21B | 887.90M |
| EPS Basic | 7.58 | 8.53 | 12.40 | 13.25 | 6.70 |
| Normalized Basic EPS | 4.55 | 6.97 | 8.23 | 7.28 | 5.33 |
| EPS Diluted | 7.27 | 8.07 | 11.54 | 12.41 | 6.27 |
| Normalized Diluted EPS | 4.37 | 6.59 | 7.65 | 6.82 | 4.99 |
| Average Basic Shares Outstanding | 106.70M | 107.60M | 108.10M | 108.10M | 107.80M |
| Average Diluted Shares Outstanding | 111.20M | 113.80M | 116.20M | 115.40M | 115.10M |
| Dividend Per Share | 0.88 | -- | -- | -- | -- |
| Payout Ratio | 11.60% | -- | -- | -- | -- |